
Overview
Rigel Q2 2025 revenue of $101.7 mln beats analyst expectations, per LSEG data
Company reports Q2 net income of $59.6 mln, reversing a loss from last year
Net product sales grew 76% yr/yr, driven by TAVALISSE and GAVRETO
Outlook
Rigel updates 2025 revenue guidance to $270-$280 mln
Company expects net product sales of $210-$220 mln in 2025
Rigel forecasts $60 mln in contract revenues from collaborations
Company anticipates positive net income for full-year 2025
Result Drivers
NET PRODUCT SALES - Rigel's net product sales increased by 76% year-over-year, driven by TAVALISSE and GAVRETO
NON-CASH REVENUE - Recognized $40 mln in non-cash revenue from agreement with Eli Lilly, contributing to contract revenues
INTERNATIONAL EXPANSION - Launch of TAVALISSE in South Korea by partner Kissei contributed to sales growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $101.70 mln | $88.90 mln (3 Analysts) |
Q2 EPS |
| $3.28 |
|
Q2 Net Income |
| $59.6 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc is $23.50, about 3.5% above its August 4 closing price of $22.67
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago
Press Release: ID:nPn9cRZ7Ka